Trexquant Investment LP Purchases Shares of 5,658 Gilead Sciences, Inc. (NASDAQ:GILD)

Trexquant Investment LP purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,658 shares of the biopharmaceutical company's stock, valued at approximately $523,000.

Several other hedge funds also recently made changes to their positions in the company. McAdam LLC raised its stake in shares of Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock worth $2,344,000 after buying an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock valued at $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Gilead Sciences by 3.9% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock worth $13,132,000 after buying an additional 5,382 shares during the last quarter. Global Financial Private Client LLC raised its holdings in shares of Gilead Sciences by 1,222.0% in the 4th quarter. Global Financial Private Client LLC now owns 6,068 shares of the biopharmaceutical company's stock worth $561,000 after purchasing an additional 5,609 shares during the period. Finally, Exome Asset Management LLC acquired a new position in Gilead Sciences during the third quarter valued at approximately $4,192,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Remove Ads

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders sold 300,285 shares of company stock valued at $30,274,875. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Wells Fargo & Company upped their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley upped their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Finally, Oppenheimer upped their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $105.12.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ:GILD traded up $0.33 during trading on Wednesday, reaching $106.01. 869,148 shares of the company traded hands, compared to its average volume of 7,470,499. The firm has a market cap of $132.00 billion, a P/E ratio of 286.16, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a fifty day simple moving average of $108.63 and a 200 day simple moving average of $97.11.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.98%. The ex-dividend date was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.